WAVECREST Post Market Clinical Follow-Up (PMCF) Study

Not Applicable

Terminated

• Conditions: Non-valvular Atrial Fibrillation
• Interventions: Device: Percutaneous LAA Closure; Drug: Anticoagulation or Clopidogrel

• Registration Number: NCT03204695
• Lead Sponsor: Coherex Medical

Brief Summary

The WAVECREST PMCF Study is a prospective, non-randomized, multicenter study to confirm safety and performance of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System in the current medical practice setting in patients with non-valvular atrial fibrillation who are at increased risk for stroke. Up to 65 subjects may be enrolled at up to 15 study sites in Europe. Patients will be followed through 45 days post-procedure.

Detailed Description

The Coherex WaveCrest® Left Atrial Appendage Occlusion System is designed to permanently occlude the Left Atrial Appendage (LAA).

Study Timeline

• Study Start: 2017-05-29
• Study First Submitted: 2017-06-16
• Study First Submitted QC: 2017-06-28
• Study First Posted: 2017-07-02
• Primary Completion: 2018-06-14
• Study Completion: 2018-06-14
• Status Verified: 2024-03
• Results First Submitted: 2024-03-26
• Results First Submitted QC: 2024-03-26
• Last Update Submitted: 2024-03-26
• Results First Posted: 2024-04-23
• Last Update Posted: 2024-04-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

1. Non-valvular paroxysmal, persistent, or permanent atrial fibrillation
2. 18 years of age or older
3. LAA anatomy amenable to treatment by percutaneous techniques
4. Risk factors for potential thrombus formation in the LAA
5. Willing to participate in the required follow-up visits and tests
6. Subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Ethics Committee or Institutional Review Board at the study site

Exclusion Criteria

1. Known contraindication to percutaneous transseptal intervention
2. Left atrial appendage anatomy or size that will not allow appropriate implantation of the WaveCrest Implant
3. Intracardiac thrombus or other cardiac abnormality visualized prior to implant that would significantly impact procedural safety
4. Mitral valve stenosis < 1.5 cm2 or any stenosis consistent with rheumatic valvular disease or history of mitral valve replacement or repair
5. Known contraindication and/or allergy to nickel
6. Known active bacterial infection (i.e., sepsis, endocarditis)
7. Any known medical condition or overall health of the subject that could adversely affect procedural safety or potentially prevent the patient from completing all study required visits and tests.
8. Pregnant or breastfeeding women due to the risk of exposure to x-rays and medications associated with the implant procedure.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
WaveCrest®	Percutaneous LAA Closure	Implant of WaveCrest® Left Atrial Appendage Occlusion System
WaveCrest®	Anticoagulation or Clopidogrel	Implant of WaveCrest® Left Atrial Appendage Occlusion System

Primary Outcome Measures

Name	Time	Method
Number of Participants With All-cause Mortality, Pericardial Effusion Requiring Intervention, Device Embolization (Major), Device Thrombus and Ischemic Stroke (Composite Primary Safety Endpoint)	From baseline up to 45 days	The primary safety outcome was the composite of death from any cause (all-cause mortality), pericardial effusion requiring intervention, device embolization (major), device thrombus and ischemic stroke up to 45 days. The analysis was based on Sponsor Assessment of Adverse Events data. Baseline was defined as the last available measurement on or before the date of the implantation procedure.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Who Achieved Device Success	From baseline up to 45 days	Percentage of participants who achieved device success were reported. Device success was defined as the percentage of participants who had the device deployed and implanted in the correct position. Baseline was defined as the last available measurement on or before the date of the implantation procedure.
Percentage of Participants Who Achieved Technical Success	From baseline up to 45 days	Percentage of participants who achieved technical success were reported. Technical success was defined as the percentage of participants who experienced successful placement and release of the occluder in the LAA with LAA closure (defined as no leak greater than \[\>\]5 millimeters \[mm\] on color Doppler transesophageal echocardiogram \[TEE\]) and who were discharged from the cardiac catheterization laboratory without the occurrence of device-related complications. Baseline was defined as the last available measurement on or before the date of the implantation procedure.
Percentage of Participants Who Achieved Procedural Success	From baseline up to 45 days	Percentage of participants who achieved procedural success were reported. Procedural success was defined as the percentage of participants who experienced successful placement and release of the occluder in the LAA with LAA closure (defined as no leak \>5 mm on color Doppler TEE) and who were discharged from the cardiac catheterization laboratory without device-related complications and without procedure-related complications other than minor device embolization (defined as device embolization that can be resolved by percutaneous technique without surgical intervention or damage to surrounding cardiovascular structures). Baseline was defined as the last available measurement on or before the date of the implantation procedure.

Trial Locations

Locations (1)

OLV Hospital; 🇧🇪 Aalst, Belgium